HERCULES, Calif. and Houston, Texas— November 4, 2022 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in…
Accelerating Precision Oncology Worldwide
Clinical and Research Laboratories
At NuProbe, we are developing innovative assays to accelerate cancer research. Our products allow laboratories to detect and quantify low-abundant variants across multiple platforms from both cell-free DNA and tissue specimens. Contact us today to learn more.
We provide assay development and testing services to support all stages of biomarker detection programs. Our flexible platform utilizes proprietary technologies to deliver best-in-class sensitivity from solid tumor and liquid biopsy. Contact one of our experts today to find out what NuProbe can do for you.
News & Press Releases
SADDLE approach uses computational primer design to minimize primer-dimer formation, and thus does not require enzymatic primers and primer-dimer removal.
JAN 25-27, 2023
Precision Medicine World Conference
FEB 15-16, 2023
Liquid Biopsy for Precision Oncology Summit
MAR 30-31, 2023
NextGen Omics US